Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.46 Average Price Target from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $92.29.

Several brokerages have recently commented on RARE. Wedbush restated a “neutral” rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday. TD Cowen boosted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, Piper Sandler increased their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the transaction, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. True Wealth Design LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at about $43,000. Values First Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth about $56,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Ultragenyx Pharmaceutical during the third quarter worth $83,000. Nomura Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $93,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $107,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 2.6 %

Shares of RARE opened at $43.16 on Thursday. Ultragenyx Pharmaceutical has a 1-year low of $37.02 and a 1-year high of $60.37. The company has a market cap of $3.99 billion, a price-to-earnings ratio of -6.67 and a beta of 0.58. The company’s fifty day simple moving average is $46.09 and its 200 day simple moving average is $49.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business’s revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.23) earnings per share. As a group, research analysts forecast that Ultragenyx Pharmaceutical will post -6.2 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.